Explore published findings of medical trials and real-world evidence.
This page includes links to Novo Nordisk-sponsored trials and observational research published in peer reviewed journals. The list of publications below is sorted by product and limited to products that have been approved for use.
Please note that publications may contain information about doses, delivery devices, uses, formulations and/or populations that differs from FDA-required labeling.
Novo Nordisk does not suggest or recommend the use of its products in any manner other than as described in their FDA-required labeling, which is findable under each product below.
Products are listed in order of the most recent FDA approval, with the most recent shown first.
(somapacitan-beco) injection 5 mg, 10 mg, 15 mg | Full Prescribing Information
Published Date: November 25, 2022
Published Date: April 1, 2020
Published Date: September 11, 2023
Published Date: April 1, 2020
Published Date: December 23, 2022
Somapacitan in children born small for gestational age: a randomized controlled phase 3 trial
Published Date: March 4, 2026
(somatropin) injection 5 mg, 10 mg, 15 mg | Full Prescribing Information
Adult growth hormone deficiency (AGHD) and outcomes (NordiNet and ANSWER).
Published Date: February 24, 2025
Comparative outcomes of GH treatment in pediatric idiopathic short stature and GH deficiency.
Published Date: August 16, 2025
Find product information
Explore our portfolio of products, including prescribing information, safety data sheets, and storage and stability information.
Continuing education
Learn about accredited disease education opportunities supported by Novo Nordisk and provided by third-party organizations.